Arrowhead Pharmaceuticals options signal 8.1% move on earnings
In short
Market participants in the options space are anticipating a sharp price reaction to the company's financial disclosure. Derivative contracts tied to Arrowhead Pharmaceuticals are pricing in an expected price swing of 8.1% around the event. This level of expected volatility highlights the substantial impact the forthcoming report is projected to have on the equity's valuation.
Key points
- Derivative markets are projecting substantial post-earnings price volatility for the biop…: Derivative markets are projecting substantial post-earnings price volatility for the biopharmaceutical equity.
- The 8.1% implied move represents the expected magnitude of the post-announcement share pr…: The 8.1% implied move represents the expected magnitude of the post-announcement share price reaction.
- Investors are using options contract pricing to anticipate risks surrounding the upcoming…: Investors are using options contract pricing to anticipate risks surrounding the upcoming report.